At RevArte in Edegem, clinicians are exploring how eye movements can reveal neurological disorders years before symptoms become visible.
Prof. Lafosse showcasing neuroClues® device
The rehabilitation hospital RevArte in Edegem (Belgium) was recently featured in Belgian media for its innovative use of neuroClues® eyetracking technology in neurological rehabilitation and cognitive assessment. In the article published by Het Nieuwsblad and Gazet van Antwerpen, Prof. Dr. Christophe Lafosse explains how subtle eye movement abnormalities may help identify brain disorders long before clinical symptoms appear.
“Hersenschuddingen, lichte beroertes en zelfs dementie”: according to the article, concussions, minor strokes, and even dementia can leave measurable signatures in eye movements years before patients notice functional impairments.
At RevArte, neuroClues® is being used to objectively quantify eye movements in patients presenting neurological or cognitive disorders. The technology captures high-frequency ocular data in only a few minutes through a portable and non-invasive CE-marked medical device.
The article highlights how eye tracking can support clinicians in detecting impairments linked to:
For Prof. Dr. Christophe Lafosse and his team, the objective is not only earlier detection, but also a more precise and measurable follow-up of patients throughout rehabilitation.
The collaboration reflects RevArte’s longstanding expertise in neurorehabilitation and quantitative cognitive assessment. Prof. Dr. Christophe Lafosse has contributed extensively to research on visuospatial deficits, neurological rehabilitation, and cognitive disorders.
RevArte has also developed innovative assessment methodologies such as the RevArte Visual Search Task, designed to quantify visual attention and neglect in brain-injured patients.
Integrating neuroClues® into this clinical environment marks another step toward delivering more objective and quantitative insights into brain health.
Eye movements provide direct insight into brain function because they involve complex neural circuits related to cognition, motor control, attention, and executive functioning.
Today, almost 30,000 scientific publications link eye movements to neurological diseases, reinforcing the growing interest in eye tracking as a clinical biomarker. neuroClues® was developed to make these measurements accessible in routine clinical practice through a fast, easy-to-use platform for neurologists and rehabilitation specialists.
The media attention around RevArte’s work reflects the increasing momentum behind objective and quantified eye movement data and the role they may play in enabling earlier and more appropriate neurological care.